|
|
|
|
|
|
|
|
|
|
CONCLUSIONS: OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use. There is no evidence that recent OC formulations increase breast cancer risk in carriers
Saturday, June 12, 2010
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis
CONCLUSIONS: OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use. There is no evidence that recent OC formulations increase breast cancer risk in carriers
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.